Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Safety and efficacy of intra-arterial bone marrow mononuclear cell transplantation in patients with acute ischaemic stroke in Spain (IBIS trial): a phase 2, randomised, open-label, standard-of-care controlled, multicentre trial

  • Moniche, Francisco
  • Cabezas, Juan A.
  • Valverde, Roberto
  • Escudero-Martínez, Irene
  • Lebrato, Lucía
  • Pardo‐Galiana, Blanca
  • Ainz-Gómez, Leire
  • Medina-Rodríguez, Manuel
  • Torre, Javier de la
  • Escamilla-Gómez, Virginia
  • Ortega-Quintanilla, Joaquín
  • Zapata‐Arriaza, Elena
  • Albóniga-Chindurza, Asier de
  • Mancha, Fernando
  • Gamero-García, Miguel Ángel
  • Pérez-Sánchez, Soledad
  • Espinosa-Rosso, Raúl
  • Forero-Diaz, Lucía
  • Moya, Miguel Ángel
  • Piñero, Pilar
  • Calderón-Cabrera, Cristina
  • Nogueras, Sonia
  • Jiménez, Rosario
  • Martin, Vanesa
  • Delgado, Fernando
  • Ochoa-Sepúlveda, Juan José
  • Quijano, Blanca
  • Mata, Rosario
  • Santos-González, Mónica
  • Carmona Sánchez, Gloria
  • Herrera, Concha
  • González-García, Alejandro
  • Montaner, Joan
[Background] Pilot clinical trials have shown the safety of intra-arterial bone marrow mononuclear cells (BMMNCs) in stroke. However, the efficacy of different doses of intra-arterial BMMNCs in patients with acute stroke has not been tested in a randomised clinical trial. We aimed to show safety and efficacy of two different doses of autologous intra-arterial BMMNC transplantation in patients with acute stroke., [Methods] The IBIS trial was a multicentre phase 2, randomised, controlled, investigator-initiated, assessor-blinded, clinical trial, in four stroke centres in Spain. We included patients (aged 18–80 years) with a non-lacunar, middle cerebral artery ischaemic stroke within 1–7 days from stroke onset and with a National Institutes of Health Stroke Scale score of 6–20. We randomly assigned patients (2:1:1) with a computer-generated randomisation sequence to standard of care (control group) or intra-arterial injection of autologous BMMNCs at one of two different doses (2 × 106 BMMNCs/kg or 5 × 106 BMMNCs/kg). The primary efficacy outcome was the proportion of patients with modified Rankin Scale scores of 0–2 at 180 days in the intention-to-treat population, comparing each BMMNC dose group and the pooled BMMNC group versus the control group. The primary safety endpoint was the proportion of serious adverse events. This trial was registered at ClinicalTrials.gov, NCT02178657 and is completed., [Findings] Between April 1, 2015, and May 20, 2021, we assessed 114 patients for eligibility. We randomly assigned 77 (68%) patients: 38 (49%) to the control group, 20 (26%) to the low-dose BMMNC group, and 19 (25%) the high-dose BMMNC group. The mean age of participants was 62·4 years (SD 12·7), 46 (60%) were men, 31 (40%) were women, all were White, and 63 (82%) received thrombectomy. The median NIHSS score before randomisation was 12 (IQR 9–15), with intra-arterial BMMNC injection done a median of 6 days (4–7) after stroke onset. The primary efficacy outcome occurred in 14 (39%) patients in the control group versus ten (50%) in the low-dose group (adjusted odds ratio 2·08 [95% CI 0·55–7·85]; p=0·28), eight (44%) in the high-dose group (1·89 [0·52–6·96]; p=0·33), and 18 (47%) in the pooled BMMNC group (2·22 [0·72–6·85]; p=0·16). We found no differences in the proportion of patients who had adverse events or dose-related events, but two patients had a groin haematoma after cell injection in the low-dose BMMNC group., [Interpretation] Intra-arterial BMMNCs were safe in patients with acute ischaemic stroke, but we found no significant improvement at 180 days on the mRS. Further clinical trials are warranted to investigate whether improvements might be possible at different timepoints., The Andalusian Network for the Design and Translation of Advanced Therapies through the Andalusian Progress and Health Public Foundation is the study sponsor. We acknowledge all the participants of the trial and the investigators. We thank the funding bodies Instituto de Salud Carlos III through the projects PI18/01414, PI15/01197, RD16/0019/0015 (INVICTUS+), and RD21/0006/0015 (co-funded by the European Regional Development Fund “A way to make Europe” and by the European Social Fund [FSE] “The FSE invests in your future”), Mutua Madrileña grant, and the Regional Ministry of Health of Andalusia, who financed the costs incurred by participating hospitals and the Andalusian Network for the Design and Translation of Advanced Therapies through the Andalusian Progress and Health Public Foundation. MM-R has a Rio Hortega grant (CM21/00096). We acknowledge the Methodological and Statistical Support Unit from the Andalusian Public Foundation for Health Research Management in Seville (FISEVI) for their support in the statistical analysis., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol

  • Medina-Rodríguez, Manuel
  • Moniche, Francisco
  • Albóniga-Chindurza, Asier de
  • Ortega-Quintanilla, Joaquín
  • Ainz-Gómez, Leire
  • Pardo‐Galiana, Blanca
  • Cabezas, Juan A.
  • Aguilar-Pérez, Marta
  • Zamora, Aynara
  • Delgado-Acosta, Fernando
  • Jiménez-Gómez, Elvira
  • Bravo-Rey, Isabel
  • Oteros-Fernández, Rafael
  • Freijo-Guerrero, Maria del Mar
  • González-Díaz, Eva
  • Escudero-Martínez, Irene
  • Morales-Caba, Lluis
  • Vielba-Gómez, Isabel
  • Mosteiro, Sonia
  • Castellanos-Rodrigo, María del Mar
  • Pascasio, Laura Amaya
  • Hidalgo, Carlos
  • Fernández-Prudencio, Luis
  • Ramírez-Moreno, José M.
  • Díaz-Pérez, José
  • Sanz-Fernández, Gema
  • Baena-Palomino, Pablo
  • Gamero-García, Miguel Ángel
  • Jiménez-Jorge, Silvia
  • Rosso-Fernández, Clara
  • Montaner, Joan
  • González-García, Alejandro
  • Zapata‐Arriaza, Elena
[Background] In-stent thrombosis after mechanical thrombectomy (MT) worsen outcomes in acute ischemic stroke (AIS) due to tandem lesions (TL). Although an optimal antiplatelet therapy is needed, the best approach to avoid in-stent thrombosis is yet to be elucidated., [Hypothesis] Low-dose intravenous tirofiban is superior to intravenous aspirin in avoiding in-stent thrombosis in patients undergoing MT plus carotid stenting in the setting of AIS due to TL., [Methods] The ATILA-trial is a multicenter, prospective, phase IV, randomized, controlled (aspirin group as control), assessor-blinded clinical trial. Patients fulfilling inclusion criteria (AIS due to TL, ASPECTS ⩾ 6, pre-stroke modified Rankin Scale ⩽2 and onset <24 h) will be randomized (1:1) at MT onset to experimental (intravenous tirofiban) or control group (intravenous aspirin). Intravenous aspirin will be administered at a 500 mg single dose and tirofiban at a 500 µg bolus followed by a 200 µg/h infusion during first 22 h. All patients will be followed up to 3 months. Sample size estimated is 240 patients., [Outcomes] The primary efficacy outcome is the proportion of patients with carotid in-stent thrombosis within the first 24 h after MT. The primary safety outcome is the rate of symptomatic intracranial hemorrhage. Secondary outcomes include functional independence defined as modified Rankin Scale 0–2, proportion of patients undergoing rescue therapy due to in-stent aggregation during MT and carotid reocclusion at 30 days., [Discussion] ATILA-trial will be the first clinical trial regarding the best antiplatelet therapy to avoid in-stent thrombosis after MT in patients with TL., [Trial registration] NCT0522596., This project was funded by the Instituto de Salud Carlos III (ISCIII) through the project PI21/01322 and co-funded by the European Union. The Spanish Clinical Research Network (SCReN-Code:21.033) also contributed to the study. The ITRIBiS project (Improving Translational Research Potential at the Institute of Biomedicine of Seville) has the registration number REGPOT-2013-1. M. Medina-Rodríguez was granted a Rio Hortega contract (CM21/00096). The project was included in the Cooperative Cerebrovascular Disease Research Network (INVICTUS) (RD16/0019/0015)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Usefulness of TNFR1 as biomarker of intracranial aneurysm in patients with spontaneous subarachnoid hemorrhage

  • de Torres-Chacón, Reyes
  • Mancha, Fernando|||0000-0003-0310-0894
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Canhao, Patricia
  • Fragata, Isabel
  • Montaner, Joan|||0000-0003-4845-2279
To determine the utility of TNF-α receptor (TNFR1) as a biomarker for the presence of aneurysms in patients with acute subarachnoid hemorrhage (SAH). This is a prospective study in patients with acute spontaneous SAH. Arterial blood from catheter near aneurysm and peripheral venous blood samples are collected. TNFR1 levels were analyzed in patients with and without aneurysm. 80 patients were included, 58 were analyzed. 41 patients (70.7%) had an aneurysm. Venous TNFR1 levels >1658 pg/ml had 46.3% sensitivity and 94.1% specificity for aneurysms presence. TNFR1 >1658 pg/ml was also an independent predictor for its presence (odds ratio = 12.03 [1.13–128.16]; p = 0.039). High levels of TNFR1 in peripheral venous blood are associated with the presence of aneurysm in patients with acute SAH. Subarachnoid hemorrhage (SAH) is a neurological emergency, in many cases caused by the rupture of a cerebral aneurysm. Usually aneurysms are detected in imaging tests, but sometimes they can be very small and go unnoticed. TNF-α is an inflammatory biomarker related to the presence and rupture of intracranial aneurysms and its receptor, TNFR1, could be detected in peripheral blood. This study demonstrates that elevated peripheral blood TNFR1 values are related to the presence of intracranial aneurysms in patients with acute subarachnoid hemorrhage. Following further research, it could become a useful tool for detecting small aneurysms in addition to conventional imaging tests.